This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Genentech's Avastin Passes Key Safety Test

Genentech (DNA) said late Thursday that its late-stage trial on Avastin in early-stage colon cancer patients passed a recent safety check and it now expects final data a year earlier than previously thought.

The South San Francisco-based company said that final efficacy and safety results for the C-08 study will now be available in 2009, rather than 2010, because of speedy data collection, patient enrollment and a higher than planned number of Stage III patients. The phase III, 2,700 patient study - which is being conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP) -- is looking at Avastin plus chemotherapy compared to the chemotherapy alone following surgery in the early-stage colon cancer patient population.

Genentech said the new timeline doesn't affect its probability of success. In conjunction with the release of abstracts for the American Society of Clinical Oncology annual meeting, the company also announced that the C-08 study received a green light from an independent data monitoring committee that conducted an interim safety and efficacy analysis in the second quarter of this year.

The board found no new or unexpected safety events in the Avastin arm in the interim check. "Due to the high cure rate for early-stage colon cancer, there is a lower acceptance of risk related to potential new therapies in the adjuvant treatment setting," said Genentech senior vice president (Clinical Hematology and Oncology) David Schenkein in a press release Thursday.

The preliminary analysis showed a similar rate of non-cancer-related deaths between the treatment arms, which was consistent with previous trials, according to the company. "Grade 3" or higher events that occurred more in the Avastin plus chemotherapy arm included hypertension, wound healing complications and pain. The company will present the safety report on Saturday, May 31 at the ASCO meeting.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,979.13 +59.54 0.35%
S&P 500 1,986.51 +4.91 0.25%
NASDAQ 4,526.4820 -1.0320 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs